Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables) - Service-Based Vesting Condition Options [Member]

3 Months Ended

Feb. 29, 2020

Variables used to determine the fair value of the options granted for the three months ended February 29, 2020 are as follows:

Stock option activity for the three months ended February 29, 2020, was as follows:


	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at November 30, 2019		1,089,774		$	3.30		3.91	$	4,648,111
Granted		44,969			7.26				813
Exercised		(20,000	)		2.05				102,800
Expired/forfeited		—			—				—

Outstanding at February 29, 2020		1,114,743		$	3.49		3.94	$	4,192,762

Exercisable at February 29, 2020		1,006,623		$	3.06		3.39	$	4,191,626

Significant option groups exercisable at February 29, 2020 and related price and contractual life information are as follows:


	Outstanding						Exercisable
Range of Exercise Prices	Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Outstanding		Weighted Average Exercise Price
$1.01 to $2.00		422,500		1.85	$	1.73		422,500	$	1.73
$2.01 to $3.00		245,000		1.85	$	2.78		245,000	$	2.78
$3.01 to $4.00		204,729		5.98	$	3.14		204,729	$	3.14
$6.01 to $7.00		3,833		6.35	$	6.52		2,111	$	6.51
$7.01 to $8.00		238,681		7.99	$	7.57		132,283	$	7.62

		1,114,743		3.94	$	3.49		1,006,623	$	3.06

A summary of the status of the Company’s

non-vested

options as of February 29, 2020, and changes during the three months ended February 29, 2020, is presented below:


	Options			Weighted Average Grant-Date Fair Value
Non-vested at November 30, 2019		125,234		$	4.70
Granted		44,969			5.03
Vested		(62,083	)		4.51
Forfeited		—			—

Non-vested at February 29, 2020		108,120		$	4.95